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Purpose
The aim of the current study was to determine the incidence, clinical presentation, and
treatment outcomes of “bone-only metastases”in patients with breast cancer and to analyze
the impact of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2)
status on prognosis.
Materials and Methods
Between 1994 and 2007, of 968 patients with metastatic breast cancer who underwent
palliative management at Samsung Medical Center, 565 (57%) relapsed with distant
metastases. Of the 968, 146 (15%) had bone-only metastases during a median follow-up period
of 75 months. Among the 146 patients with bone-only metastases, 122 (84%) were relapsed
patients after curative surgery and 24 (26%) were initially metastatic cases.
Results
The median time from primary surgery to bone-only metastases of the 122 patients was 37
months (95% confidence interval [CI], 27 to 46 months). Bone-only metastases were more
common in the HR-positive group than in the other subtypes (85% for HR+; 8.2% for HER2+;
6.8%for triple negative. Among all 146 patients, 75 (51%) were treated with hormone therapy.
The median post-relapse progression-free survival was 15 months (95%CI, 13 to 17 months).
The median overall survival was much longer in the HR+ patients than the HER2+ and triple
negative breast cancer patients with marginal statistical significance (65 vs. 40 vs. 40
months, p=0.077). 
Conclusion
Breast cancer patients with “bone-only metastases” had excellent clinical outcomes.
Further study is now warranted to reveal the underlying biology that regulates the behavior
of this indolent tumor, as it should identify ‘favorable tumor characteristics’ in addition to
‘favorable preferential metastatic site.’
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Introduction
Bone is the most common site of metastatic recurrence in breast
cancer and bone metastases are a major cause of morbidity for
patients with metastatic breast cancer (MBC) [1]. Bone represents
the first site of metastasis inĥ50% of patients who fail systematically
[2,3]. After Sherry et al. [4,5] reported that MBC confined to the
skeletal system is highly responsive to treatment and associated with
prolonged survival, the concept of bone-only metastasis as a first site
of relapse emerged. Bone-only metastasis means bone metastasis
without evidence of any other organ involvement. Although metastatic
spread to most end organs occurs by similar mechanisms [6,7], and
survival is almost always poor in patients with extensive disease
involving multiple organs, bone-only metastasis in breast cancer
patients appears to show a relatively good prognosis [2,4,5,8]. For
endocrine-sensitive breast cancer, the National Comprehensive
Cancer Network (NCCN) guideline recommends endocrine therapy
for the management of MBC confined to the bone and soft tissue [9].One of the most intriguing biological aspects of metastasis is the
pattern of organ dissemination [10]. Aggressive tumor cells typically
enter the blood stream and reach distant tissues. This dissemination
has stereotypical patterns of organ tropism that reflects the hetero-
geneity of tumor cells and depends on the cancer type. Estrogen
receptor (ER)-positive tumors preferentially spread to bone. Recent
data supports the view that bone metastasis is associated with the
absence of Wnt signaling [11]. Considering that most bone metastases
are associated with an indolent disease course and clinical dormancy,
these cases may have characteristic clinical features with predomi-
nance of dormancy over aggressive metastatic disseminations. 
Hence, we undertook this study; 1) to determine the incidence,
clinical course, and treatment outcomes for breast cancer patients
with of “bone-only metastases”; and 2) to analyze the impact of
hormone receptor and human epidermal growth factor receptor 2
(HER2) status on the prognosis of this group. 
Materials and Methods
We retrospectively reviewed the medical records of patients with
pathologically-confirmed invasive breast cancer who received palli-
ative management between October 1994 and March 2007 at Samsung
Medical Center. Among 968 MBC patients who had distant relapse,
565 (58.4%) had bone metastases. Of the 565, 146 (25.8%) had
bone-only metastasis as the first distant site of relapse. Bone-only
metastasis was defined as bone metastasis without evidence of
involvement of any other organ. The following patient information
was obtained from medical records: gender; age; prior treatment;
primary treatment after bone metastasis; presence of progression to
other metastatic sites; distant relapse-free survival (DRFS); post-relapse
overall survival (PR-OS); and PR progression-free survival (PFS). 
ER and progesterone receptor (PgR) positivity was defined as an
Allred score from 3-8 by immunohistochemistry (IHC) using anti-
bodies to the ER (Immunotech, Paris, France) and PgR (Novocastra,
Newcastle, UK). HER2 status was evaluated using an antibody
(Dako, Carpinteria, CA) and/or fluorescence in situ hybridization
(FISH). Grades 0 and 1 for HER2 by IHC were defined as a negative
result, and grade 3 as a positive result. Amplification of HER2 was
confirmed by FISH if HER2 was rated 2+ by IHC. All core biopsies
from referral institutes were reviewed by experienced pathologists in
our institute including IHC staining at the time of initial referral. The
pathology reviews for all surgical specimens were done prospec-
tively and comprehensively by experienced pathologists in our
institute. Our study protocol was approved by the Institutional Review
Board of Samsung Medical Center.
1 Treatments
After documentation of bone metastasis, patients received palliative
local and/or systemic treatment. The agents used in hormonal therapy
included tamoxifen, goserelin, and aromatase inhibitors (letrozole
and anatrozole), according to menopausal status. Systemic chemo-
therapeutic regimens, including doxorubicin and taxanes, were given
at the physician’s discretion or the patients’ preference. Anti-HER2
therapy with chemotherapy or hormonal therapy was administered
for HER2 overexpressing metastatic breast cancer. Bisphosphonate
treatment was performed at the physician’s discretion, with or without
hormonal therapy and/or chemotherapy. 
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968 MBC pts. who received
palliative treatment identified from October 1994 to March 2008
403 MBC pts.
without bone
metastasis
565 MBC pts.
who had bone metastasis
419 MBC pts. who had
other distant metastasis
with bone metastasis
146 MBC pts.
who had bone-only
distant metastasis
Fig. 1. Patient cohort. MBC pts, patients with metastatic breast cancer.2 Statistical analysis
DRFS was defined as the time from the date of curative surgery
of breast cancer to the date of documentation of distant relapse. PR-
OS was measured from the date of distant relapse to the date of death
or the last follow-up day. PR-PFS was measured from the date of
distant relapse to the date of documented disease progression or death.
PR-PFS (other distant) was confined to progression to other distant
metastasis besides progression to bone metastasis. PFS and OS were
defined as the same for all 146 patients with bone-only metastases
including 24 patients presented as stage IV at the time of diagnosis.  
Clinicopathologic variables were compared between the “bone-
only metastasis” group and the “other metastasis” group, and hormone
receptor-positive and -negative patients in the bone-only metastasis
group using the Pearson chi-square (Ȅ
2) test and Fisher's exact test
for categorical variables. Survival curves were calculated using the
Kaplan-Meier method and compared with other prognostic variables
using the log-rank test. A p-valueģ0.05 was considered significant.
A Cox proportional hazards regression model was used to assess the
effect of each potential prognostic variable on PR-OS and PR-PFS.
Results
1 Patient characteristics (Fig. 1)
The median duration of follow-up of all 146 patients with bone-
only metastases was 75 months (range, 28 to 124 months).
The clinical characteristics of the patients who relapsed with bone
metastasis only are summarized in Table 1. The median age was 47
years (range, 18 to 76 years). High nuclear and histologic grades
were noted in 24.7% and 26.7%, respectively. Eighty-five percent
were ER+ and/or PR+; the rest were HER2+ (8.2%) and triple
negative breast cancer (TNBC) (6.8%). Of the 146 patients, 122
(83.6%) relapsed to bone metastasis after surgery; the remaining 24
(16.4%) were initially metastatic. Among the 122 (83.6%) relapsed
patients, 91.8% received adjuvant hormonal therapy. Single bone
metastasis occurred in 23.3% of the patients. The median number of
involved bones was 2 (range, 1 to 5). Extensive bone metastases,
defined as10 bones being involved with or without bone
destruction or soft tissue formation, were demonstrated in 23.3%.
The most commonly involved bone was the spine (55.5%). After
palliative treatment, common progression sites were bone (73.3%)
and lung (19.2%). The progression site was limited to bone in
55.5% of patients. The main treatment modality was hormonal
therapy with or without radiation (45.9%). Systemic chemotherapy
was administered to 28.1% of patients with or without radiation.
Bisphosphonate therapy was administered to 68.5% of patients. The
median time of bisphosphonate therapy was 15.6 months (range, 0.7
to 71.9 months). The 5-year survival rate after documentation of
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Table 1. Characteristics of 146 bone-only breast cancer patients
Characteristics No. of patiens (%)
Age
Median (range, yr) 47 (18-76)
Nuclear grade 
I 3/95 (2.1)
II 56/95 (38.4)
III 36/95 (24.7)
Histologic grade 
I 6/88 (5.7)
II 43/88 (29.5)
III 39/88 (26.7)
Breast cancer subtypes
HR+(ER+and/or PR+) 124 (85.0)
HER2+(HER2+/ER-/PR-) 12 (8.2)
TNBC (ER-/PR-/HER2-) 10 (6.8)
p53 positive 40/118 (27.2)
Stage
1 15 (10.3)
2 50 (34.3)
3 57 (39.0)
4 24 (16.4)
Adjuvant treatment (n=122)
Chemotherapy 114 (93.4)
Radiation therapy 70 (57.3)
Endocrine therapy 112 (91.8)
Single bone metastasis 34 (23.3)
Median numbers of involved areas  2
Extensive bone metastases 34 (23.3)
Involved bones 
Spine 81  (55.5)
Pelvis 62 (42.5)
Rib 53 (36.3)
Sternum 26 (17.8)
Femur 26 (17.8)
Humerus 5 (3.5)
Clavicle 4 (2.7)
Progression sites
Multiple bones 107 (73.3)
Initial metastatic bone-only 81 (55.5)
Lung   28 (19.2)
Liver 22 (15.1)
Lymph nodes 20 (13.7)
Brain 12  (8.2)
Pleura 11  (7.5)
Treatment for metastatic diseases (first-line treatment)
Endocrine therapy   54 (36.9)
Chemotherapy 27  (18.5)
Radiation therapy  19 (13.0)
Radiation therapy+chemotherapy 15  (10.3)
Radiation therapy+endocrine therapy  13 (8.9)
Supportive care 12 (8.2)
Chemotherapy+targeted therapy 6 (4.1)
History of biophosphonate treatment 100 (68.5) 
1-yr PFSR 59.4
5-yr OSR  52.7
HR, hormone receptor; ER, estrogen receptor; PR, progesterone receptor; HER2,
human epidermal growth factor receptor 2; TNBC, triple negative breast cancer;
PFSR, progression free survival rate; OSR, overall survival rate.bone metastasis for a median follow-up duration of 75 months was
52.3%. 
2 Clinical outcomes
HR+ patients had superior, but not statistically significant metastatic
OS compared to HER2+ and TNBCs patients (Fig. 2). The median
PR-OS of HR+ breast cancer patients was 65 months. Conversely,
the median OS of both HER2+ and TNBCs patients was 40 months,
respectively (p=0.077).
Comparing the 34 patients with a single bone metastasis to the
112 patients with multiple bone metastases, much better outcomes
(in terms of PR-PFS and PR-OS) occurred in patients with single
bone metastasis, as expected. Median PR-PFS values for patients
with single and multiple bone metastases were 24 and 14 months,
respectively (p=0.002) (Fig. 3A). Median PR-OS values for these
patients were 79 and 50 months (p=0.005) (Fig. 3B). 
3 Clinicopathologic characteristics according to DRFS
We divided patients into two groups according to a DRFS of 36
months in order to characterize metastatic behavior of bony pre-
ferences of metastasis in terms of the time of metastasis. There were
significant differences in mean age, histologic grade, adjuvant hor-
monal therapy, and involved bone sites between patients who had a
DRFS of 36 months and those who had an DRFSģ36 months
(Table 2). The numbers of patients for each group were 60 and 62,
respectively. The mean age was younger in patients with a DRFS
ģ36 months than in patients with a DRFS36 months (46 years vs.
50 years, p=0.041 by t-test). More patients with a DRFS36
months were HR+ than patients with a DRFSģ36 months, but
statistical significance was not reached (91.8% vs. 80.0%, p=0.156).
Higher histologic grade (54.8% vs. 35.0%, p=0.072) and nuclear
grade (50.0% vs. 26.7%, p=0.024) were more common in patients
with a DRFSģ36 months. The spine was more commonly involved
in patients with a DRFSģ36 months (62.1% vs. 43.5%, p=0.042).
The sternum was not frequently involved in patients with a DRFS
ģ36 months (8.6% vs. 27.4%, p=0.009). Adjuvant hormonal
therapy was administered for patients with a DRFS36 months
more commonly than patients with a DRFSģ36 months (80.0% vs.
55.9%, p=0.005). A greater percentage of patients with a DRFSģ36
months had liver (25.0% vs. 6.7%, p=0.011) and lung progression
(26.7% vs. 11.7%, p=0.037) than patients with a DRFS36 months.
The 1-year PR-progression free survival rate was 53.8% vs. 62.5%;
the 5-year overall survival rate (OSR) was 50.0% vs. 72.6% (p=0.010).
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Fig. 3. Progression free survival (PFS) (A) and overall survival (OS) (B) between the patients with single and multiple bone involvement; green
line represents survival of patients with single bone metastasis; blue line represents survival of patients with multiple bone metastases.
0.0
1.0
Probability
(mo)
0.0
192.0 144.0 120.0 96.0 72.0 48.0 24.0
0.8
0.6
0.4
0.2
168.0
HR+ (n=124)
HER2+ (n=12)
TNBC (n=10)
Median OS
65 vs. 40 vs. 40 mo
p=0.077
Fig. 2. Overall survival (OS) from metastasis according to breast
cancer subtypes. Blue line represents OS of hormone receptor (HR)-
(+) patients; green line represents OS of human epidermal growth
factor receptor 2 (HER2)-(+) patients; red line represents OS of triple
negative breast cancer (TNBC) patients.
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p=0.002
0.0
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0.8
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0.4
0.2
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Multiple (n=112)
Single (n=34)
Median OS
50 vs. 79.4 mo
p=0.004
192.0
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Characteristics
DRFSģ36 mo  DRFS36 mo 
p-value
(n=60) (%) (n=62) (%)
Mean age (±SD) 46 (±11.7) 50 (±11.2) 0.041 (t-test)
Initial stage 3 30 (50.8) 26 (42.6) 0.137
Subtypes (n=121) 0.156
HR+(ER+and/or PR+) 48 (80.0) 57 (91.9)
HER2+(ER-/PR-/HER2+) 6 (10.0) 2 (3.2)
TNBC (ER-/PR-/HER2-) 6 (10.0) 3 (4.9)
Histologic type
IDC vs. non-IDC 50 (94.3) 50 (90.9) 0.716
Histologic grade (n=82)
High (Grade 3) 23 (54.8) 14 (35.0) 0.072
Nuclear grade (n=89)
High (Grade 3) 22 (50.0) 12 (26.7) 0.024
Adjuvant chemotherapy (n=121) 57 (95.0) 56 (91.8) 0.717
Adjuvant endocrine therapy (n=112) 33 (55.0) 48 (77.4) 0.005
Involved bone sites
Spine 62.1 43.5 0.042
Pelvis 47.4 32.3 0.092
Sternum 8.6 27.4 0.009
Femur 19.0 16.1 0.683
Humerus 5.2 0 0.110
Rib   41.4 35.5 0.507
Skull 8.8 11.5 0.764
Clavicle 3.3 3.2 0.237
Single bone metastasis 3 (5.0) 31 (50.0) ģ0.0001
Extensive bone metastases
a) 15 (25.9) 10 (16.1) 0.190
Skeletal events
b) 14 (24.1) 7 (11.3) 0.064
Progression sites
Bone 78.3 71.7 0.399
Liver 25.0 6.7 0.011
Lung 26.7 11.7 0.037
Lymph nodes 11.7 8.3 0.762
Pleura 13.3 1.7 0.032
Brain 10.0 6.7 0.743
1 yr PR-PFSR 53.8 62.5 0.362
5 yr PR-OSR 50.5 72.6 0.010
Table 2. Comparison of clinicopathologic characteristics according to duration of DRFS for relapsed patients (n=122)
DRFS, distant relapse free survival; SD, standard deviation; HR, hormone receptor; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor
receptor 2; TNBC, triple negative breast cancer; IDC, invasive ductal carcinoma; PFSR, progression free survival rate; OSR, overall survival rate. 
a)Extensive bone metastases,10
bones involvement with or without bone destruction soft tissue formation, 
b)Skeletal events, associated with bone metastases as pain, fracture, and limit of motion.
Significance (p-value) Hazard ratio
95% CI
Lower Upper
DRFS36 mo 0.038 0.450 0.211 0.958
Single bone metastasis 0.003 0.280 0.121 0.646
High histological grade 0.005 3.211 1.429 7.217
Table 3. Cox-regression multivariate analysis for PR-OS
The other factors that had not revealed any significance were adjusted in this multivariate analysis. PR-OS, post-relapse overall survival; CI, confidence interval; DRFS, distant
relapse free survival.Cancer Res Treat. 2011;43(2):89-95
94 CANCER  RESEARCH AND  TREATMENT
4 Cox regression multivariate analysis for PR-OS (Table 3)
Single bone metastasis was identified as a favorable independent
prognostic factor for PR-OS (hazard ratio [HR], 0.280; p=0.003)
with a DRFS36 months (HR, 0.280; p=0.038). High histologic
grade was identified as an unfavorable independent risk factor for
PR-OS (HR, 3.211; p=0.005). 
Discussion
Breast cancer with bone-only metastases is thought to be associated
with a relatively favorable prognosis compared with breast cancer
with other visceral metastatic sites. Clearly, breast cancer prefe-
rentially spreads to bone [12,13]. According to Paget's “seed” and
“soil” hypothesis, the perceived compatibilities between disseminated
cancer cells (the seed) and certain distant sites (the soil) have long
influenced the view of the metastatic process [14]. Considering that
metastasis is the end product of an evolutionary process involving
diverse interactions between cancer cells and their microenvironment,
bone metastasis may be a good example to show a favorable outcome
with the indolent disease course of breast cancer, even when there is
distant metastasis. Recurrence after curative resection and durable
remission is not infrequent. In fact, 20-45% of patients with breast
cancer relapse years or decades later [15-17]. To address the role of
bone as a single distant end organ in the metastatic process of breast
cancer, we analyzed late-onset relapse with a DRFS36 months
separately. According to our results, late-onset relapses after a DRFS
36 months developed more in the HR+ subgroup with a low
histologic grade (Table 2). In addition, these late-onset relapses con-
fined to bone showed an excellent outcome of 72.6% in terms of the
5-year PR-OSR. The objective tumor burden as metastasis proceeds
might be the main problem. A pause in progression has to be
considered the most likely explanation for the discrepancy between
the estimated and observed disease-free periods [18]. To understand
this dormancy, cells must be characterized during the dormant state.
Given the results that many of the late-onset bone-only metastatic
breast cancers progressed to bone with visceral metastasis, bone
may provide a good microenvironmental condition to maintain the
‘dormant state.’  
Traditionally, this ‘favorable preference to the bone’ in breast cancer
is known to have a relationship with the ER [15,19,20]. The rate of
late-onset metastasis was significantly higher in ER+ cases. ER+
breast tumors relapse most prominently to the bones over a prot-
racted period [20]. Furthermore, the overall rate of bone metastasis and
the rate of late-onset bone metastasis were significantly higher in
ER+ cases than in ER- cases [21,22]. This finding is also supported
by our data. Most of the breast cancer subtypes in bone-only
metastasis were HR+ (Table 2). Recently, some plausible data
explaining the relationship between ER and bone metastases has
been reported. Specifically, transforming growth factor-ǰ /bone
morphogenic proteins have been reported to have a role in bone
metastasis together with the epithelium-to-mesenchyme transition
[21]. In addition, there is a report that Src selectively promotes bone
metastasis in ER+ breast cancers and supports the idea that there is
survival of indolent breast cancer cells in bone marrow [19]. Src is
the prototypic member of the non-receptor tyrosine kinase family.
Src participates in the activation of various downstream pathways
through molecular interactions with growth factor receptors
(epidermal growth factor receptor and HER2), integrin cell adhesion
receptors, steroid hormone receptors, G protein-coupled receptor,
focal adhesion kinase, and cytoskeleton components [23]. The
importance of these candidate biomarkers is increased by the urgent
need for development of new treatment targets as well as for
understanding tumor biology. The identification of mechanisms that
support the survival of disseminated cancer cells in their host
microenvironments has clear implications for improving the
treatment of latent metastatic disease. Survival of indolent and latent
tumors eventually results in tumor recurrence. Thus, further prolon-
gation of latency or a permanent stop in dormancy can be equated to
‘cancer-free’ life.   
Cleary, this study was limited by its being a retrospective analysis
and by the small size of the bone-only metastases group. Despite
these drawbacks, our study successfully demonstrated the clinical
characteristics and disease course of bone-only metastases in breast
cancer patients. This is from a homogeneous cohort from a single
institution with a sizable sample and a long follow-up duration.   
Conclusion
The bone-only metastases in breast cancer show excellent clinical
outcomes, which developed mainly in the HR+ subgroup. A further
study to determine how to regulate this indolent tumor behavior is
warranted because it would help identify ‘favorable tumor charac-
teristics’ in addition to ‘favorable preferential metastatic site.’
Conflicts of Interest
Conflict of interest relevant to this article was not reported.Su Jin Lee, et al_Bone-only Metastasis in Breast Cancer
VOLUME 43  NUMBER 2  JUNE  2011   95
1. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(8 Suppl):1588-94.
2. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer.
Br J Cancer. 1987;55:61-6.
3. ParkinDM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49:33-64, 1.
4. Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Breast cancer with skeletal
metastases at initial diagnosis. Distinctive clinical characteristics and favorable
prognosis. Cancer. 1986;58:178-82.
5. Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Metastatic breast cancer
confined to the skeletal system: an indolent disease. Am J Med. 1986;81:381-6.
6. Lee YT. Patterns of metastasis and natural courses of breast carcinoma. Cancer
Metastasis Rev. 1985;4:153-72.
7. Kamby C, Ejlertsen B, Andersen J, Birkler NE, Rytter L, Zedeler K, et al. The pattern of
metastases in human breast cancer: influence of systemic adjuvant therapy and
impact on survival. Acta Oncol. 1988;27:715-9.
8. Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following
bone recurrence from breast cancer. Br J Cancer. 1998;77:336-40.
9. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. Breast
cancer: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009;7:122-92.
10. Nguyen DX, Massagué J. Genetic determinants of cancer metastasis. Nat Rev Genet.
2007;8:341-52.
11. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, et al. Subtypes of breast
cancer show preferential site of relapse. Cancer Res. 2008;68:3108-14.
12. Chiang AC, Massagué J. Molecular basis of metastasis. N Engl J Med. 2008;359:2814-23.
13. Lacroix M. Significance, detection and markers of disseminated breast cancer cells.
Endocr Relat Cancer. 2006;13:1033-67.
14. Paget S. The distribution of secondary growths in cancer of the breast. Lancet.
1889;133:571-3.
15. Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after
mastectomy. J Natl Cancer Inst. 1999;91:80-5.
16. Pfitzenmaier J, Ellis WJ, Arfman EW, Hawley S, McLaughlin PO, Lange PH, et al.
Telomerase activity in disseminated prostate cancer cells. BJU Int. 2006;97:1309-13.
17. Weckermann D, Müller P, Wawroschek F, Harzmann R, Riethmüller G, Schlimok G.
Disseminated cytokeratin positive tumor cells in the bone marrow of patients with
prostate cancer: detection and prognostic value. J Urol. 2001;166:699-703.
18. Demicheli R. Tumour dormancy: findings and hypotheses from clinical research on
breast cancer. Semin Cancer Biol. 2001;11:297-306.
19. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, et al. Latent bone
metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell.
2009;16:67-78.
20. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, et al.
From latent disseminated cells to overt metastasis: genetic analysis of systemic
breast cancer progression. Proc Natl Acad Sci U S A. 2003;100:7737-42.
21. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy
and hormonal therapy for early breast cancer on recurrence and 15-year survival: an
overview of the randomised trials. Lancet. 2005;365:1687-717.
22. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN. Estrogen receptors and distinct
patterns of breast cancer relapse. Breast Cancer Res Treat. 2003;78:105-18.
23. Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src family kinases
and receptor tyrosine kinases. Oncogene. 2004;23:7957-68.
References